Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

A final-stage clinical trial comparing a new long-acting, once-weekly pill to treat schizophrenia symptoms with the existing daily treatment has found that both produce comparable therapeutic effects.

Researchers at Rutgers University-New Brunswick (N.J.) are questioning the FDA’s 2020 decision to place a safety warning on a common antiseizure medication. Lamictal (lamotrigine), a GSK medicine ...

Clinical improvements were achieved and maintained for up to 3 years among bDMARD-naïve patients with PsA who received bimekizumab.